Cardiac and renal complications of carfilzomib in patients with multiple myeloma
| Autor: | Nikolaos Kanellias, Magdalini Migkou, Constantinos Pamboukas, Efstathios Manios, Argyrios Ntalianis, Sofoklis Kontogiannis, Maria Gavriatopoulou, Erasmia Psimenou, Elektra Papadopoulou, Despina Fotiou, Efstathios Kastritis, Evangelos Terpos, Maria Roussou, Ioannis Panagiotidis, Dimitrios C. Ziogas, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Kimon Stamatelopoulos |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Creatinine Ejection fraction Lymphoid Neoplasia business.industry Incidence (epidemiology) Urology Renal function Hematology urologic and male genital diseases Carfilzomib Nephrotoxicity Discontinuation 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry immune system diseases 030220 oncology & carcinogenesis hemic and lymphatic diseases Toxicity medicine business 030215 immunology |
| Zdroj: | Blood advances. 1(7) |
| ISSN: | 2473-9529 |
| Popis: | Clinical trials with carfilzomib have indicated a low but reproducible incidence of cardiovascular and renal toxicities. Among 60 consecutive myeloma patients treated with carfilzomib-based regimens who were thoroughly evaluated for cardiovascular risk factors, 12% (95% confidence interval, 3.8%-20%) experienced a reversible reduction of left ventricular ejection fraction (LVEF) by ≥20%, an objective measure of cardiac dysfunction. The incidence of LVEF reduction was 5% at 3 months, 8% at 6 months, 10% at 12 months, and 12% at 15 months, whereas the respective carfilzomib discontinuation rate unrelated to toxicity was 17%, 35%, 41%, and 49%. The presence of any previously known cardiovascular disease was associated with an increased incidence of cardiac events (23.5% vs 7%; P = .07), but there was no association with the dose of carfilzomib or the duration of infusion. Re-treatment with carfilzomib at lower doses was possible. Carfilzomib was commonly associated with a transient reduction of estimated glomerular filtration rate (eGFR) but also improved renal function in 55% of patients with baseline eGFR |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|